Associated Papers
Inotuzumab therapy resulted in molecular remission of relapsed/resistant B-cell acute lymphoblastic leukemia with BCR::ABL1 Lys404Glu mutation.
Lewandowski K et al.
Annals of Hematology, 2025
Rare damaging variants in the sex differences of congenital heart disease: an exome sequencing study.
Sun H et al.
Ebiomedicine, 2025
40347836 (PubMed )
Supplement: mmc4.xlsx › Supplementary_Table_9
Treatment-Emergent Resistance to Asciminib in Chronic Myeloid Leukemia Patients Due to Myristoyl-Binding Pocket-Mutant of BCR::ABL1/A337V Can Be Effectively Overcome with Dasatinib Treatment.
Batar P et al.
Current Oncology (toronto, Ont.), 2025
Overcoming Secondary Mutations of Type II Kinase Inhibitors.
Wang X et al.
Journal of Medicinal Chemistry, 2024
Characterization of Asciminib-Resistant Philadelphia Chromosome-Positive Cells.
Okabe S et al.
World Journal of Oncology, 2024
In vitro evidence of synergistic efficacy with asciminib combined with reduced dose of ATP-binding pocket tyrosine kinase inhibitors according to the ABL1 kinase domain mutation profile.
Han HJ et al.
Leukemia, 2024
Discovery and characterization of novel potent BCR-ABL degraders by conjugating allosteric inhibitor.
Liu H et al.
European Journal of Medicinal Chemistry, 2022
The Dawn of Allosteric BCR-ABL1 Drugs: From a Phenotypic Screening Hit to an Approved Drug.
Teng M et al.
Journal of Medicinal Chemistry, 2022
Development of asciminib, a novel allosteric inhibitor of BCR-ABL1.
Réa D et al.
Critical Reviews in Oncology/hematology, 2022
Genomic Mechanisms Influencing Outcome in Chronic Myeloid Leukemia.
Fernandes A et al.
Cancers, 2022
Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.
Eide CA et al.
Cancer Cell, 2019
BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in Philadelphia chromosome-positive leukemia.
Antelope O et al.
Experimental Hematology, 2019
Molecular dynamics investigation on the Asciminib resistance mechanism of I502L and V468F mutations in BCR-ABL.
Zhan JY et al.
Journal of Molecular Graphics & Modelling, 2019
The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro.
Eadie LN et al.
Oncotarget, 2018
Identification and characterization of activating ABL1 1b kinase mutations: impact on sensitivity to ATP-competitive and allosteric ABL1 inhibitors.
Lee BJ et al.
Leukemia, 2017
Select a paper to view details